| [1] |
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
|
| [2] |
程若川，杨婷婷. 2016版中国甲状腺微小乳头状癌诊断与治疗专家共识解读[J]. 中国实用内科杂志, 2019, 39(4): 351-357.
|
| [3] |
高明，魏松锋. 不断提高分化型甲状腺癌外科诊治规范化水平[J/CD]. 中华普外科手术学杂志(电子版), 2016, 10(5): 361-364.
|
| [4] |
宋创业，孟艳林，尚培中, 等. 乳腺癌双侧甲状腺转移一例并文献复习[J]. 中华转移性肿瘤杂志, 2019, 2(1): 47-50.
|
| [5] |
张磊，董云伟，胡神保, 等. 美国癌症联合委员会甲状腺癌分期系统(第8版)修订对甲状腺乳头状癌分期的影响[J]. 中国癌症杂志, 2018, 28(7): 491-496.
|
| [6] |
Wang J, Liu J, Pan H, et al. Young age increases the risk of lymph node positivity in papillary thyroid cancer patients: A SEER data-based study[J]. Cancer Manag Res, 2018, 10: 3867-3873.
|
| [7] |
Magreni A, Bann DV, Schubart JR, et al. The effects of race and ethnicity on thyroid cancer incidence[J]. JAMA Otolaryngol Head Neck Surg, 2015, 141(4): 319-323.
|
| [8] |
韩婧，康骅. 甲状腺癌的发病现状及影响因素[J].实用预防医学, 2018, 25(7): 894-897.
|
| [9] |
张荣天，张多钧，雷鸣, 等. 内蒙古西部地区甲状腺癌危险因素分析[J/CD]. 国际感染病学(电子版), 2019, 8(3): 211-212.
|
| [10] |
Gábora K, Bărbuş E, Peştean C, et al. Radiation induced thyroid carcinoma in Romania-effects of the Chernobyl fallout, a systematic review of observational studies[J]. Clujul Med, 2018, 91(4): 372-375.
|
| [11] |
张虹，陈建华，魏巍，等. 乌鲁木齐甲状腺癌相关危险因素调查研究[J]. 中国全科医学, 2016, 19(12): 1446-1450.
|
| [12] |
Roche AM, Fedewa SA, Shi LL, et al. Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer[J]. Cancer, 2018, 124(8): 1780-1790.
|
| [13] |
郑向前，候秀坤，高明. 2017年第二版NCCN甲状腺肿瘤指南解读[J]. 中国肿瘤临床, 2018, 45(1): 14-17.
|
| [14] |
陈孝平，汪建平. 外科学[M]. 8版. 北京: 人民卫生出版社, 2018: 244.
|
| [15] |
Lu HZ, Qiu T, Ying JM, et al. Association between BRAFV600E mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma[J]. Oncol Lett, 2017, 13(3): 1595-1600.
|
| [16] |
吴光锋，范瑞，王博. 甲状腺乳头状癌中CK19 Galectin-3 CyclinD1和CD56的表达和意义[J]. 实用医技杂志, 2017, 24(10): 1135-1137.
|
| [17] |
Mohamed DA, Shamlola MM. Immunohistochemical and morphometrical evaluation of well-differentiated thyroid tumor of uncertain malignant potential[J]. Indian J Pathol Microbiol, 2019, 62(1): 17-23.
|
| [18] |
毛康，徐建博，杨彦民, 等. Galectin-3、IL-17在甲状腺癌诊断中的应用价值[J]. 齐齐哈尔医学院学报, 2018, 39(3): 326-327.
|
| [19] |
Kaptan E, Sancar Bas S, Sancakli A, et al. Runt-related transcription factor 2 (Runx2) is responsible for Galectin-3 overexpression in human thyroid carcinoma[J]. J Cell Biochem, 2017, 118(11): 3911-3919.
|
| [20] |
史剑飞，卢北玲，黄博, 等. 新生血管内皮生长因子EG-VEGF/PROK1在肿瘤中的研究进展[J]. 现代肿瘤医学, 2018, 26(22): 3682-3686.
|
| [21] |
Mohamad Pakarul Razy NH, Wan Abdul Rahman WF, Win TT. Expression of vascular endothelial growth factor and its receptors in thyroid nodular hyperplasia and papillary thyroid carcinoma: A tertiary health care centre based study[J]. Asian Pac J Cancer Prev, 2019, 20(1): 277-282.
|
| [22] |
刘池拽，师天雄，邓建伟, 等. p27蛋白在结节性甲状腺肿和甲状腺癌中的表达及意义[J]. 热带医学杂志, 2011, 11(6): 641-643.
|
| [23] |
Abdou AG, Abdelwahed M, Said A, et al. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study[J]. J Immunoassay Immunochem, 2018, 39(5): 521-537.
|
| [24] |
潘在兴，蒋翡翎，姚敏, 等. BRAFT1799A在甲状腺乳头状癌患者外周血中的表达及其临床意义[J]. 分子诊断与治疗杂志, 2018, 10(4): 246-251.
|
| [25] |
王松，项承，王平. 甲状腺癌相关基因检测进展及意义[J]. 中国实用外科杂志, 2019, 39(3): 268-270, 274.
|
| [26] |
Xu X, Ma X, Zhang X, et al. Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR[J]. Clin Chim Acta, 2019, 491: 91-96.
|
| [27] |
Zhang X, Wang L, Wang J, et al. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma[J]. Exp Mol Pathol, 2018, 105(1): 153-159.
|
| [28] |
Valvo V, Nucera C. Coding molecular determinants of thyroid cancer development and progression[J]. Endocrinol Metab Clin North Am, 2019, 48(1): 37-59.
|
| [29] |
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3): 184-199.
|
| [30] |
王欣怡，白俊文. 甲状腺癌的相关基因BRAF、RET、RAS研究新进展[J]. 重庆医学, 2018, 47(36): 4631-4634.
|
| [31] |
Kure S, Wada R, Naito Z. Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma[J]. Med Mol Morphol, 2019, 52(4): 181-186.
|
| [32] |
Su X, Li Z, He C, et al. Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: A Meta-analysis[J]. Oncotarget, 2016, 7(13): 16716-16730.
|
| [33] |
Vuong HG, Long NP, Anh NH, et al. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: A Meta-analysis[J]. Endocr Connect, 2018, 7(12): R286-R293.
|
| [34] |
李仕亮，孙纷纷，邵国安, 等. 甲状腺癌中PTEN蛋白表达与BRAF~(V600E)突变的相关性研究[J]. 现代肿瘤医学, 2017, 25(6): 871-875.
|